International Brazilian Journal of Urology (Jun 2023)

Holmium laser enucleation of the prostate (HoLEP) is safe and effective in patients with high comorbidity burden

  • Fabrizio Di Maida,
  • Antonio Andrea Grosso,
  • Riccardo Tellini,
  • Samuele Nardoni,
  • Sofia Giudici,
  • Anna Cadenar,
  • Vincenzo Salamone,
  • Luca Lambertini,
  • Matteo Salvi,
  • Andrea Minervini,
  • Agostino Tuccio

DOI
https://doi.org/10.1590/s1677-5538.ibju.2022.0174
Journal volume & issue
Vol. 49, no. 3
pp. 341 – 350

Abstract

Read online Read online

ABSTRACT Introduction We assessed the efficacy and safety of holmium laser enucleation of the prostate (HoLEP) in patients with high comorbidity burden. Materials and methods Data from patients treated with HoLEP at our academic referral center from March 2017 to January 2021 were prospectively collected. Patients were divided according to their CCI (Charlson Comorbidity Index). Perioperative surgical data and 3-month functional outcomes were collected. Results Out of 305 patients included, 107 (35.1%) and 198 (64.9%) were classified as CCI ≥ 3 and 0.05). Intraoperative complications rate (9.3% vs. 9.5%, p=0.77), median time to catheter removal and hospital stay were comparable between the two cohorts. Similarly, early (30 days) and delayed (>30 days) surgical complications rates were not significantly different between the two groups. At 3-month follow up, functional outcomes using validated questionnaires did not differ between the two groups (all p>0.05). Conclusions HoLEP represents a safe and effective treatment option for BPH also in patients with high comorbidity burden.

Keywords